Hangzhou Minsheng Healthcare Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Hangzhou Minsheng Health Pharmaceutical Co., Ltd. is a subsidiary of Hangzhou Minsheng Pharmaceutical Holding Group in the major health industry, located in Yuhang Economic and Technological Development Zone. The company focuses on the field of vitamin and mineral supplements, and is a high-tech enterprise that integrates the research and development, production, and sales of over-the-counter vitamin and mineral drugs and health food. The current main product of the company is the 21 Golden Vita Multidimensional Element Tablets (21). In recent years, the company has fully utilized its accumulated brand advantages, technological advantages, quality control advantages, operational management advantages, and customer resource advantages to meet the diverse vitamin and mineral supplementation needs of different age groups, providing a precise population of health food products. This business segment has seen rapid revenue growth and has become a new business growth point for the company. After completing the acquisition of Minsheng Health Technology in 2020, the company's product system expanded to the probiotic series, further enriching the product matrix. After years of industry cultivation, the company has built a nationwide terminal sales network system, with strong brand awareness and reputation. The company's main brand is "21 Golden Vita". In 2019, it was listed on the "Healthy China · Brand List" Xipu Gold Award Sharp List, and in 2020, it was listed on the "Healthy China · Brand List" Xipu Gold Award Drug List. In 2021, it was selected as the "2020 2021 Health Industry · Brand Development Index · TOP Brand". The company always adheres to making product quality the top priority of its production and operation. From supplier selection, raw material inspection, product production process to finished product inspection, all aspects are strictly implemented in accordance with GMP requirements and the company's quality standards, ensuring that the quality of products ultimately flowing to the market meets the requirements of laws and regulations. The company and its subsidiaries have 49 authorized patents, including 5 invention patents, 14 utility model patents, 29 appearance patents, and 1 Australian patent, forming a complete set of product formulas, production processes, and micro vitamin detection methods, including multi nutrient synergistic effect ratio technology, micronutrient mixing uniformity control method, vitamin and mineral tablet product stability control technology, and micro vitamin detection method The core technical system for quality control and inspection. This technical system is the source of the company's current product market competitiveness and also the endogenous driving force for future business growth. |
| Headquarter | Hangzhou |
| Establish Date | 12/14/2009 |
| Listed Code | 301507.SZ |
| Listed Date | 9/5/2023 |
| Chairman | Zhu Fujiang. |
| CEO | Zhang Haijun. |
| Website | www.21vita.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
